Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0

Puri, S.; B. Leighl, Natasha; Ismaila, Nofisat; Abu Rous, Fawzi; Ahluwalia, Amith; Alluri, Krishna; Azar, Ibrahim; Campbell, Toby; Andrew Durm, Greg; Feldman, Jill; Florez, Narjust; Freeman-Daily, Janet; Furuya, Naoki; Gadgeel, Shirish; Halmos, Balazs; Horinouchi, Hidehito; Kuruvilla, Sara; R. MacVicar, Gary; K. Malhotra, Narinder; A. Marrone, Kristen; Raj Mishra, Deebya; P. Mullane, Michael; Naidoo, Jarushka; Owen, Dwight; Pellini, B.; J. Presley, Carolyn; Qin, Angel; Roof, Logan; L. Schenk, Erin; VanDam Sequist, Lecia; Singh, Navneet; K. Singhi, Eric; Marie Suga, J.; I. Velázquez, Ana; Wang, Yubao; Wheatley Price, Paul; Reuss, J.; Bazhenova, Lyudmila

doi:10.1200/jco-25-02822

Public

Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0

Published in Journal of Clinical Oncology • Feb 3, 2026

Authors:

S. Puri

Natasha B. Leighl

Nofisat Ismaila

Abstract

This guideline has been updated. This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the online dynamic version for the latest updates. ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following t...

Subject

Medicine

Oncology

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!